Sanli Yasemin, Simsek Duygu Has, Sanli Oner, Subramaniam Rathan M, Kendi Ayse Tuba
Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34093, Turkey.
Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34093, Turkey.
Biomedicines. 2021 Apr 15;9(4):430. doi: 10.3390/biomedicines9040430.
The aim of this narrative review is to evaluate the current status of Lu-PSMA (prostate specific membrane antigen) therapy for metastatic castration-resistant prostate cancer (mCRPC) in the light of the current literature. We also addressed patient preparation, therapy administration and side effect profiles. Lu-PSMA therapy efficacy was assessed by using prospective trials, meta-analyses and major retrospective trials. Predictors of efficacy were also mentioned. Although there are some different approaches regarding the use of Lu-PSMA therapy in different countries, this type of therapy is generally safe, with a low toxicity profile. From the oncological point of view, a PSA (prostate specific antigen) decline of ≥50% was seen in 10.6-69% of patients with mCRPC; whereas progression-free survival (PFS) was reported to be 3-13.7 months in different studies. Consequently, Lu-PSMA therapy is a promising treatment in patients with mCRPC, with good clinical efficacy, even in heavily pretreated patients with multiple lines of systemic therapy. Currently, there are ongoing clinical trials in the United States, including a phase III multicenter FDA registration trial.
本叙述性综述的目的是根据当前文献评估镥-前列腺特异性膜抗原（Lu-PSMA）疗法治疗转移性去势抵抗性前列腺癌（mCRPC）的现状。我们还探讨了患者准备、治疗给药和副作用情况。通过前瞻性试验、荟萃分析和大型回顾性试验评估了Lu-PSMA疗法的疗效。文中还提到了疗效的预测因素。尽管不同国家在使用Lu-PSMA疗法方面存在一些不同的方法，但这类疗法总体上是安全的，毒性较低。从肿瘤学角度来看，mCRPC患者中10.6%-69%的患者前列腺特异性抗原（PSA）下降≥50%；而在不同研究中，无进展生存期（PFS）据报道为3-13.7个月。因此，Lu-PSMA疗法对于mCRPC患者是一种有前景的治疗方法，具有良好的临床疗效，即使是接受过多种系统治疗的重度预处理患者也是如此。目前，美国正在进行临床试验，包括一项III期多中心FDA注册试验。
